{"schema":"sb.node.v1","id":"sb:e/e13bda76f6012ea6ca00515a","kind":"entity","label":{"text":"asco","locale":"en"},"identity":{"anchor":"label:en:asco","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-10T17:30:17.444527+00:00","snapshot":"deploy d3689e88c5960e221ab0ad8059cbed523c0447fc"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":64,"separatePublishers":21,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim","receiptsOnTopic":{"state":"partial","share":0.25,"named":16,"of":64,"basis":"documents whose own title or summary lead names the subject, over every counted document that mentions it anywhere (the entity graph's measurement); receipts are drawn from the former only","blind":["only 25% of the 64 documents measured name the subject in their own text; the rest mention it in passing, so standing.evidence.supporting overstates coverage about it"]}},"admission":{"state":"canonical","reason":"entity graph provenance 'curated'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-06-03","to":"2026-10-08","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.203: about 80% of mentions carry no typed assertion"]}},"dimensions":{"domains":["society_news","oncology"],"activeDays":30,"assertions":{"regulatory-approval":8,"meeting-visit":5}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":8,"byKind":{"observation":8},"withheld":{"state":"withheld","count":4,"reason":"4 receipts withheld: no source link (the same rule the topic record applies)"},"items":[{"id":"sb:o/b44cfae576e8b1dda77dfe1f","kind":"observation","label":"Energies Media · 2026-09-25 · ASCO opens Teesside office at Wilton Centre to support Net Zero Teesside and offshore wind projects","url":"https://energiesmedia.com/asco-teesside-office-wilton-centre/"},{"id":"sb:o/91fd91ca5d58994df773e903","kind":"observation","label":"European Medical Journal · 2026-09-23 · ASCO 2026: Elizabeth Mittendorf on ASCO Leadership","url":"https://www.emjreviews.com/oncology/video/asco-2026-elizabeth-mittendorf-on-asco-leadership/"},{"id":"sb:o/e86f953434c69af5a0d0b418","kind":"observation","label":"The ASCO Post · 2026-09-10 · The 2026 ASCO Annual Meeting Geriatric Oncology Update: The Next Challenge Is Implementation","url":"https://ascopost.com/issues/september-10-2026/the-2026-asco-annual-meeting-geriatric-oncology-update-the-next-challenge-is-implementation/"},{"id":"sb:o/7936bf79d591c18062e927f8","kind":"observation","label":"The ASCO Post · 2026-10-07 · GLP-1 Receptor Agonist Use Linked to Lower Colorectal Cancer Risk in Patients With Inflammatory Bowel Disease","url":"https://ascopost.com/news/october-2026/glp-1-receptor-agonist-use-linked-to-lower-colorectal-cancer-risk-in-patients-with-inflammatory-bowel-disease/"},{"id":"sb:o/021b61cbabf1df8164366b81","kind":"observation","label":"OncoDaily · 2026-09-20 · Debra Patt: Thoughtful AI Adoption Can Reduce Administrative Burden and Improve Care Delivery","url":"https://oncodaily.com/voices/debra-patt-589460"},{"id":"sb:o/4137d5d4ac2f50d073362186","kind":"observation","label":"The ASCO Post · 2026-09-10 · cfDNA Fragmentomics Plus Methylation Analysis May Improve Detection of Precancerous Colorectal Lesions","url":"https://ascopost.com/issues/september-10-2026/cfdna-fragmentomics-plus-methylation-analysis-may-improve-detection-of-precancerous-colorectal-lesions/"},{"id":"sb:o/c1a0b22a188c848ed59de757","kind":"observation","label":"The ASCO Post · 2026-09-10 · Structured Exercise After Adjuvant Chemotherapy for Colon Cancer Improves Survival and Saves Costs","url":"https://ascopost.com/issues/september-10-2026/structured-exercise-after-adjuvant-chemotherapy-for-colon-cancer-improves-survival-and-saves-costs/"},{"id":"sb:o/951ae761112d41f9baaa5278","kind":"observation","label":"The ASCO Post · 2026-09-10 · GLP-1 Receptor Agonists Linked to Lower Colorectal Cancer Risk in Patients With IBD","url":"https://ascopost.com/issues/september-10-2026/glp-1-receptor-agonists-linked-to-lower-colorectal-cancer-risk-in-patients-with-ibd/"}],"cursor":null,"order":"newest first; we keep the 8 newest receipts for this entity whose own title or summary lead (the entity graph's test) names it. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":{"state":"cannot-measure","reason":"claims: this subject's maintained record could not be read (the maintained record \"asco\" could not measure its claims: this subject was retired from the publication registry on 2026-09-17 (no longer clears the admission conditions — re-checked 2026-09-17 (sources its own coverage — 6 of 6 receipts name it in the source line and 1 name it in a headline, which is a publication rather than a subject its own press covers)); the record is kept as a dated tombstone and is no longer maintained). The items listed come from the passes that could be read"},"byKind":{"co-mentioned":10},"items":[{"kind":"relation","label":"co-mentioned with fda (25 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/2093cc3a48c94d887d741042"},{"kind":"relation","label":"co-mentioned with colorectal cancer (24 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/31a163a9424f6a3e3964497a"},{"kind":"relation","label":"co-mentioned with immunotherapy (23 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/72f80d42f01fc3f79770549b"},{"kind":"relation","label":"co-mentioned with her2 (19 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/1cb8d46c489a07329a8074c4"},{"kind":"relation","label":"co-mentioned with breast cancer (19 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/d0babe88020bcce5ae62ef78"},{"kind":"relation","label":"co-mentioned with asco annual meeting (16 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/07a0f565980110ddf60370de"},{"kind":"relation","label":"co-mentioned with lung cancer (16 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/93ed91d90112cbd322dbf040"},{"kind":"relation","label":"co-mentioned with american society (15 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/33f84843ad824b7ca9b5e989"},{"kind":"relation","label":"co-mentioned with kras (13 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/0ec0b2a239242490875d5df2"},{"kind":"relation","label":"co-mentioned with china (12 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/49fe11643344b4425c1ec737"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/e13bda76f6012ea6ca00515a","mcp":"traverse {\"id\":\"sb:e/e13bda76f6012ea6ca00515a\"}","page":"/entity/asco/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/e13bda76f6012ea6ca00515a\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/e13bda76f6012ea6ca00515a\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/e13bda76f6012ea6ca00515a\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/e13bda76f6012ea6ca00515a\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}